Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action

被引：1

作者：

Benlloch, Salvador ^{[1
,2
]}

Moncho, Francesc ^{[3
]}

Gorriz, Jose Luis ^{[3
,4
]}

机构：

[1] Hosp Arnau Vilanova, Serv Med Digest, Valencia, Spain

[2] Inst Salud Carlos III, CIBERehd, Madrid, Spain

[3] Hosp Clin Univ Valencia, Serv Nefrol, INCLIVA, Valencia, Spain

[4] Univ Valencia, Valencia, Spain

来源：

NEFROLOGIA | 2024年 / 44卷 / 02期

关键词：

Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Hepatic steatosis; Chronic kidney disease; Liver fibrosis; Type 2 diabetes mellitus; LIFE-STYLE MODIFICATION; SIGNIFICANT FIBROSIS; RISK; NAFLD;

D O I：

10.1016/j.nefro.2023.08.005

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Non-alcoholic fatty liver disease or metabolic-associated fatty liver disease (MAFLD) is a common condition with increasing prevalence and incidence, specially in patients with type 2 diabetes mellitus (DM2). Both cardiovascular and renal disease are clearly increased in these patients, particularly in those with diabetic nephropathy. In the liver-heart-kidney-metabolic axis, the common pathophysiological basis of MAFLD, cardiovascular disease (CVD), chronic kidney disease (CKD), and DM2 is the same. The clinical relationship between all of them is clear and is multidirectional: MAFLD may precede the development of cardiovascular and renal disease, and may also worsen the prognosis of these complications once developed. In this review we emphasize the importance of targeting MAFLD in diabetic kidney disease, with the goal of detecting high-risk patients in order (c) 2023 Sociedad Espa & ntilde;ola de Nefrolog & iacute;a. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/

引用

页码：129 / 138

页数：10

共 50 条

[1] The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis [J].

Agustanti, Nenny ;

Soetedjo, Nanny Natalia Mulyani ;

Damara, Fachreza Aryo ;

Iryaningrum, Maria Riastuti ;

Permana, Hikmat ;

Bestari, Muhamad Begawan ;

Supriyadi, Rudi .

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (05)

[2] Diabetic Kidney Disease Challenges, Progress, and Possibilities [J].

Alicic, Radica Z. ;

Rooney, Michele T. ;

Tuttle, Katherine R. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12) :2032-2045

[3] Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH [J].

Ampuero, Javier ;

Aller, Rocio ;

Gallego-Duran, Rocio ;

Crespo, Javier ;

Luis Calleja, Jose ;

Garcia-Monzon, Carmelo ;

Gomez-Camarero, Judith ;

Caballeria, Joan ;

Lo Iacono, Oreste ;

Ibanez, Luis ;

Garcia-Samaniego, Javier ;

Albillos, Agustin ;

Frances, Ruben ;

Fernandez-Rodriguez, Conrado ;

Diago, Moises ;

Soriano, German ;

Andrade, Raul J. ;

Latorre, Raquel ;

Jorquera, Francisco ;

Morillas, Rosa Maria ;

Escudero, Desamparados ;

Estevez, Pamela ;

Hernandez Guerra, Manuel ;

Augustin, Salvador ;

Banales, Jesus M. ;

Aspichueta, Patricia ;

Benlloch, Salvador ;

Miguel Rosales, Jose ;

Salmeron, Javier ;

Turnes, Juan ;

Romero-Gomez, Manuel .

JOURNAL OF HEPATOLOGY, 2020, 73 (01) :17-25

[4] Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis [J].

Ampuero, Javier ;

Pais, Raluca ;

Aller, Rocio ;

Gallego-Duran, Rocio ;

Crespo, Javier ;

Garcia-Monzon, Carmelo ;

Boursier, Jerome ;

Vilar, Eduardo ;

Petta, Salvatore ;

Zheng, Ming-Hua ;

Escudero, Desamparados ;

Luis Calleja, Jose ;

Aspichueta, Patricia ;

Diago, Moises ;

Miguel Rosales, Jose ;

Caballeria, Joan ;

Gomez-Camarero, Judith ;

Lo Iacono, Oreste ;

Benlloch, Salvador ;

Albillos, Agustin ;

Turnes, Juan ;

Banales, Jesus M. ;

Ratziu, Vlad ;

Romero-Gomez, Manuel ;

Agustin, Salvador ;

Jorquera, Francisco ;

Frances, Ruben ;

Garcia-Samaniego, Javier ;

Salmeron, Javier ;

Fernandez-Rodriguez, Conrado ;

Estevez, Pamela ;

Andrade, Raul ;

Soriano, German ;

Fernandez-Bermejo, Miguel ;

Arias Loste, Maria Teresa ;

Siguenza, Rebeca ;

Giannetti, Aurora ;

del Pozo Maroto, Elvira .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (01) :216-+

[5] The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].

Angulo, Paul ;

Hui, Jason M. ;

Marchesini, Giulio ;

Bugianesi, Ellisabetta ;

George, Jacob ;

Farrell, Geoffrey C. ;

Enders, Felicity ;

Saksena, Sushma ;

Burt, Alastair D. ;

Bida, John P. ;

Lindor, Keith ;

Sanderson, Schuyler O. ;

Lenzi, Marco ;

Adams, Leon A. ;

Kench, James ;

Therneau, Terry M. ;

Day, Christopher P. .

HEPATOLOGY, 2007, 45 (04) :846-854

[6] Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus [J].

Aubert, Lucia ;

Sandino, Justo ;

Gutierrez-Solis, Elena ;

Garcia-Martin, Florencio ;

Segura, Julian ;

Porrini, Esteban ;

Morales, Enrique .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (06) :1125-1131

[7] Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS [J].

Borisov, Angel N. ;

Kutz, Alexander ;

Christ, Emanuel R. ;

Heim, Markus H. ;

Ebrahimi, Fahim .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (11) :2940-2949

[8] NAFLD as a driver of chronic kidney disease [J].

Byrne, Christopher D. ;

Targher, Giovanni .

JOURNAL OF HEPATOLOGY, 2020, 72 (04) :785-801

[9] Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease [J].

Cai, Xiaoyan ;

Sun, Lichang ;

Liu, Xiong ;

Zhu, Hailan ;

Zhang, Yang ;

Zheng, Sulin ;

Huang, Yuli .

THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12

[10] Cardiometabolic HFpEF: NASH of the Heart [J].

Capone, Federico ;

Vettor, Roberto ;

Schiattarella, Gabriele G. .

CIRCULATION, 2023, 147 (06) :451-453

← 1 2 3 4 5 →